Validation and Forced Degradation Studies for the Determination of Erlotinib in Bulk and Pharmaceutical Dosage Forms by RP-HPLC
Keywords:
Erlotinib, RP-HPLC, validation, Forced degradation studies, ICH guidelinesAbstract
Abstract
A new reverse phase-high performance liquid chromatography (RP-HPLC) have been developed and validated for the determination of Erlotinib in bulk drug and pharmaceutical dosage form. The developed method is rapid, accurate, precise, simple and economical. The separation was carried out using column Hypersil ODS C-18 (150 mm x 4.6 mm 5 μm particle size) in isocratic mode, using mobile phase composition of 0.1% orthophosphoric acid: Acetonitrile in the ratio of 20:80 and PH adjusted to 4.0±0.1 with 1 M sodium hydroxide. The flow rate was 1.0 ml/min effluents are monitored at 245 nm. Chromatogram showed peak at a retention time of 2.706 min for Erlotinib. The method is validated according to ICH guidelines system suitability, linearity, precision, accuracy, specificity, ruggedness, robustness, LOD and LOQ. The calibration plot showed good linear relationship with r2 = 0.999 in the concentration range of 25-150 μg/ml for Erlotinib. The LOD and LOQ were found to be 1.07 μg/ml and 3.24 μg/ml. Accuracy was found to be 99.89%. Erlotinib was also exposed to acidic, alkaline, oxidative, thermal and photolytic conditions and the stressed samples were analyzed by the proposed method. Degradation studies showed that the Erlotinib was highly stable under acidic, alkaline, oxidative, thermal and photolytic conditions without change in RT values compared to standard and no significant degraded peaks were observed. The high percentage of stability under stress conditions confirms the suitability of the method for the determination of Erlotinib in pure and marketed formulations.
Cite this Article
K. Kalyani, V. Anuradha, Rlc. Sasidhar et al. Validation and Forced Degradation Studies for the Determination of Erlotinib in Bulk and Pharmaceutical Dosage Forms by RP-HPLC. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2016; 3(2): 44–53p.
Downloads
Published
Issue
Section
License
Copyright Transfer and Declaration Form (Please compile this form, sign and send by e-mail and post)
Journal Title:
Title of the Paper:
Corresponding Author’s Information: Name: Address:
E-mail:
Contact Number: I
t is herein agreed that: The copyright to the above-listed unpublished and original article is transferred to STM Journals. This copyright transfer covers the exclusive right to reproduce and distribute the contribution, including reprints, translations, photographic reproductions, microform, electronic form (offline, online), or any other reproductions of similar nature. I/We declare that above manuscript is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere. I/ We warrant(s) that his/her/their contribution is original, except for such excerpts from copyrighted works as may be included with the permission of the copyright holder and author thereof, that it contains no libelous statements, and does not infringe on any copyright, trademark, patent, statutory right, or propriety right of others. I/We will not publish his/her/their above said contribution anywhere else without the prior written permission of the publisher unless it has been changed substantially.I/We also agree to the authorship of the article in the following order:Author(s) Name Signature(s)
1. ________________
2. _______________
_3. ________________
4. ________________
The author(s) agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal (comments if any to the editor can be added below).
